What to know about the new drug trial for Alzheimer's – Hartford Courant

PHILADELPHIA — A new drug designed to ward off Alzheimer's is being tested at more than 100 sites around the world, including the University of Pennsylvania. Called lecanemab, it consists of antibodies that bind to the abnormal proteins that accumulate in the brains of people with Alzheimer's. Previous efforts to target these proteins have resulted in little to no improvement in patient ...

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,California ,Plymouth Meeting ,Japan ,Massachusetts ,Philadelphia ,Japanese ,Chris Hemsworth ,National Institutes Of Health ,Harvard Medical School ,National Institutes ,Southern California ,Therapeutic Research Institute ,Massachusetts General Hospital ,Harvard Medical ,Keystone Clinical Studies ,Health And Wellness ,Treatments And Therapies ,Medicinal Drugs ,Antibody Therapy ,Drug And Device Approval Process ,Drug Testing And Approval Process ,Medical And Pharmaceutical Regulation ,Biotechnology ,Biopharmaceuticals ,Immunotherapeutics ,Pharmaceuticals ,Healthcare ,Medical Diagnostic Equipment ,Medical Imaging Equipment ,Manufacturing ,Medical Device Manufacturing ,Medical Devices ,North America ,Americas ,